Placeholder

LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the Central Nervous System (CNS) to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders.  Axial’s focus is to develop gut-selective, best-in-class therapies to treat CNS-based disorders by targeting the gastrointestinal tract.  The Company was founded in December 2016 with a $19M Series A co-led by Domain and Longwood.

  • David Donabedian Co-Founder, CEO and Director